This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 3
  • /
  • Merck announces filing of form 10 registration sta...

Merck announces filing of form 10 registration statement in connection with planned spinoff of Organon & Co..

Read time: 1 mins
Published:19th Mar 2021
Merck announced that it has filed a Form 10 registration statement with the United States Securities and Exchange Commission (“SEC”) in connection with the intended spinoff of its women’s health, biosimilars and established brands businesses into a standalone, publicly-traded company, Organon.If all conditions are met, the separation is on track for completion late in the second quarter of 2021. Organon will be a global healthcare company formed through a spinoff from Merck to focus on improving the health of women throughout their lives. It will have a portfolio of more than 60 trusted medicines that address an entire spectrum of conditions women face and other medical needs. Led by the growing reproductive health portfolio including patent-protected Nexplanon (etonogestrel implant), coupled with an expanding biosimilars business and stable franchise of established medicines.
Condition: Contraception
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.